Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease
- 1 March 2015
- journal article
- review article
- Published by Elsevier BV in Brain Research
- Vol. 1600, 17-31
- https://doi.org/10.1016/j.brainres.2014.12.027
Abstract
No abstract availableKeywords
Funding Information
- University College London Comprehensive Biomedical Research Centre
- Moorfields Biomedical Research Centre
- Dutch MS Research Foundation (grants 09-687 MS and 09-358 d MS)
This publication has 99 references indexed in Scilit:
- Caspase Cleavage of GFAP Produces an Assembly-Compromised Proteolytic Fragment that Promotes Filament AggregationASN Neuro, 2013
- GFAP Expression as an Indicator of Disease Severity in Mouse Models of Alexander DiseaseASN Neuro, 2013
- Single molecule enzyme-linked immunosorbent assays: Theoretical considerationsJournal of Immunological Methods, 2012
- Axonal damage in the making: Neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matterExperimental Neurology, 2011
- Pathogenic T cell responses against aquaporin 4Acta Neuropathologica, 2011
- Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar DegenerationJournal of Proteome Research, 2010
- Strategies for Treatment in Alexander DiseaseNeurotherapeutics, 2010
- Oligomers of Mutant Glial Fibrillary Acidic Protein (GFAP) Inhibit the Proteasome System in Alexander Disease Astrocytes, and the Small Heat Shock Protein αB-Crystallin Reverses the InhibitionOnline Journal of Public Health Informatics, 2010
- Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MSJournal of Neuroimmunology, 2007
- GFAP Versus S100B in Serum after Traumatic Brain Injury: Relationship to Brain Damage and OutcomeJournal of Neurotrauma, 2004